(CVKD) |
|
0 (0%)
|
03-26 23:55 |
|
Open: |
|
Pre. Close: |
|
|
High:
|
|
Low:
|
|
|
Volume:
|
0 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:25:08 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 2.34 One year: 2.77 |
| Support: |
Support1: 1.41 Support2: 1.18 |
| Resistance: |
Resistance1: 2.01 Resistance2: 2.37 |
| Pivot: |
1.74 |
| Moving Average: |
MA(5): 1.52 MA(20): 1.86
MA(100): 0 MA(250): 0 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3  |
| Stochastic oscillator: |
%K(14,3): 6.4 %D(3): 6.6 |
| RSI: |
RSI(14): 20.7 |
| 52-week: |
High: 6.09 Low: 1.41 |
| Average Vol(K): |
3-Month: 0 (K) 10-Days: 47 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CVKD ] has closed above bottom band by 9.0%. Bollinger Bands are 0% narrower than normal. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.58 - 1.59 |
1.59 - 1.6 |
|
Low:
|
1.41 - 1.42 |
1.42 - 1.43 |
|
Close:
|
1.42 - 1.43 |
1.43 - 1.44 |
|
Company Description |
|
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. |
Headline News |
Tue, 14 Mar 2023
'Dodged a bullet': How fall of SVB is affecting First Coast companies - The Business Journals
Thu, 09 Mar 2023
Cadrenal Therapeutics Recognizes National Kidney Month with ... - Valdosta Daily Times
Tue, 28 Feb 2023
Horizon Technology Finance Announces Fourth Quarter and Full ... - PR Newswire
Mon, 27 Feb 2023
Pre-market Movers: MLEC, CFRX, AWIN, TGNA, BRMK… - Nasdaq
Wed, 08 Feb 2023
Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing ... - PR Newswire
Tue, 24 Jan 2023
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
12 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
69.2 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
20 (K) |
|
Shares Short P.Month
|
4 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.15 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-10.22 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
